Director/PDMR Shareholding
24 5월 2023 - 8:00PM
Director/PDMR Shareholding
DXS INTERNATIONAL PLC
Notification of Director / PDMR Dealing
The Board of DXS International plc (the
“Company”), the AQSE Growth Market quoted clinical decision support
developer and supplier of clinical decision support systems
confirms that the Placing Shares and the Stakeholder Shares
referred to in the Announcement of 17th May have this morning been
admitted to trading on the Aquis Stock Exchange.
As part of the Placing and Conversion of Debt DL
Services Limited, (a company owned and controlled by the Chief
Executive’s wife), has been issued with 753,244 Ordinary Shares in
the Company at the Placing Price of 4p per share.
Following the transaction specified above Mr
Immelman’s interests, including those of persons closely associated
with him, is 6,523,829 Ordinary Shares representing 10.19% of the
issued share capital of the Company.
|
1 |
Details of the person discharging managerial
responsibilities / person closely associated |
|
a) |
Name |
DL Services Limited |
|
2 |
Reason for the notification |
|
a) |
Position/status |
a company owned and controlled by the Chief Executive’s wife |
|
b) |
Initial notification /Amendment |
Initial |
|
3 |
Details of the issuer, emission allowance market
participant, auction platform, auctioneer
or auction monitor |
|
a) |
Name |
DXS INTERNATIONAL PLC |
|
b) |
LEI |
2138001R1KEUWTXEVJ44 |
|
4 |
Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place
where transactions have been conducted |
|
a) |
Description of the financial instrument, type of instrument |
Ordinary Shares of 0.33p each |
|
|
|
|
Identification code |
ISIN GB00B2Q6HZ92 |
|
|
|
|
b) |
Nature of the transaction |
Subscription |
|
c) |
Price(s) and volume(s) |
|
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
4p |
753,244 |
|
|
|
|
|
|
|
|
d) |
Aggregated information |
|
|
|
|
|
- Aggregated volume |
|
|
|
|
|
- Price |
|
|
|
|
|
e) |
Date of the transaction |
24 May 2023 |
|
f) |
Place of the transaction |
Off market |
The Directors of DXS International plc accept
responsibility for this announcement
Enquiries:
| David
Immelman (Chief
Executive)DXS International plc |
01252 719800david@dxs-systems.com |
| Wrecclesham
HouseWrecclesham RoadFarnhamSurreyGU10 4PS |
|
|
www.dxs-systems.co.uk |
|
| Corporate
Advisor |
|
| David
PapworthCity & Merchant |
0207 101 7676 |
| Corporate
Broker |
|
|
Hybridan LLPClaire Louise
Noyce |
020 3764 2341 |
Note to Editors:
DXS International presents up to date treatment
guidelines and recommendations, from Clinical Commissioning Groups
and other trusted NHS sources, to doctors, nurses and pharmacists
in their workflow and during the patient consultation. This
effective clinical decision support ultimately translates to
improved healthcare outcomes delivered more cost effectively which
should significantly contribute towards the NHS achieving its
projected efficiency savings.
DXS (AQSE:DXSP)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
DXS (AQSE:DXSP)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024
